Evidence map›Paper›PMID 42030947›Full record

ArticleCell reports methods2026

High-throughput histopathology for complex in vitro models.

Marius F Harter, Elisa D'Arcangelo, Julien Aubert, Barbora Lavickova, Charles Havnar, Bilgenaz Stoll, Irineja Cubela, Adrian M Filip, Laura Gaspa-Toneu, Julian Scherer and 12 more

Abstract read
In one paragraph

Article in Cell reports methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Marius F HarterInstitute of Human Biology (IHB), Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Gustave Roussy Cancer Campus, University Paris-Saclay, Paris, France.
Elisa D'ArcangeloInstitute of Human Biology (IHB), Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Julien AubertInstitute of Human Biology (IHB), Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Barbora LavickovaInstitute of Human Biology (IHB), Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Charles HavnarDepartment of Pathology, Genentech, Inc., South San Francisco, CA, USA.
Bilgenaz StollInstitute of Human Biology (IHB), Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Irineja CubelaInstitute of Human Biology (IHB), Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Adrian M FilipInstitute of Human Biology (IHB), Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Laura Gaspa-ToneuInstitute of Human Biology (IHB), Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Julian SchererInstitute of Human Biology (IHB), Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Evdoxia KaragkioziRoche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
Jean-Samuel DupréInstitute of Human Biology (IHB), Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Rubén López-SandovalInstitute of Human Biology (IHB), Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Rebecca HsiaComplex in vitro Systems Group, Genentech, Inc., South San Francisco, CA, USA.
Leah M NoronaPredictive Toxicology, Genentech, Inc., South San Francisco, CA, USA.
Giovanna BrancatiInstitute of Human Biology (IHB), Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Immunology and Regenerative Medicine, Genentech, Inc., South San Francisco, CA, USA.
Ryo OkudaInstitute of Human Biology (IHB), Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
J Gray CampInstitute of Human Biology (IHB), Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Biozentrum, University of Basel, Basel, Switzerland.
Eliah R ShamirDepartment of Pathology, Genentech, Inc., South San Francisco, CA, USA.
Jose Luis Garcia-CorderoInstitute of Human Biology (IHB), Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland. Electronic address: jose_luis.garcia_cordero@roche.com.
Iago PereiroInstitute of Human Biology (IHB), Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland. Electronic address: pereiro@unistra.fr.
Nikolche GjorevskiInstitute of Human Biology (IHB), Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland. Electronic address: nikolche.gjorevski@roche.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histology has been a cornerstone for complex in vitro model (CIVM) characterization for decades. However, it remains a low-throughput method with time-consuming workflows. Here, we introduce a holistic "histo-workflow," utilizing 3D-printed histomolds that facilitate co-planar embedding of CIVMs at high throughput, resulting in up to 80 samples in one section. We developed a variety of model-specific histomold designs that enable spatially controlled histological sectioning and downstream analyses. We describe these workflows, including mold generation, high-plex staining, and image analysis, and exemplify their application to histological analyses of various CIVMs. Altogether, the histomolds introduced here afford opportunities for CIVM processing and analysis, while significantly reducing labor and reagent resources, thereby democratizing high-throughput handling of CIVMs in histopathology.

Indexed as

High-Throughput Screening AssaysModels, BiologicalAnimalsHumansOrganoidsPrinting, Three-DimensionalCP: imagingCP: stem cellembedding of complex in vitro modelsFFPEhigh-throughput embeddinghistopathologyimmunohistochemistrymicroarrayed tissuesmultiplex immunofluorescenceorganoid FFPE sectionsorganoids

Identifiers

PMID42030947
PMCPMC13282658

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.